International Edition
Latest News
World

Celltrion Plans 4 Biosimilar Launches in SE Asia by Feb, Says Company

Celltrion plans to launch four new biosimilars across Southeast Asia by February next year, building on market-leading positions for its existing autoimmune and oncology drugs in Singapore, Hong Kong, Malaysia and Thailand. The South Korean biopharmaceutical company will…

Celltrion plans to launch four new biosimilars across Southeast Asia by February next year, building on market-leading positions for its existing autoimmune and oncology drugs in Singapore, Hong Kong, Malaysia and Thailand.

The South Korean biopharmaceutical company will introduce the bevacizumab biosimilar Vegzelma in Hong Kong this month, followed by the ustekinumab biosimilar Steqeyma in Thailand in December, according to a company statement provided to Medical Times. An ophthalmology treatment, Eylea biosimilar Opuviz, is slated for Singapore in February, with the allergy treatment Xolair biosimilar Omlyclo arriving in Thailand the same month.

Celltrion said its direct-sales networks and hospital relationships established through current products will accelerate market entry for the follow-on biologics. The company cited IQVIA data showing its infliximab franchise, Remsima IV and SC combined, held 95% share in Singapore, 83% in Hong Kong and 75% in Malaysia during the second quarter, according to Medicaltimes. The trastuzumab biosimilar Herzuma led with 67% in Hong Kong, 59% in Thailand and 52% in Malaysia, with the Thai figure up 17 percentage points from the previous quarter.

The rituximab biosimilar Truxima recorded 92% in Singapore, 78% in Thailand and 41% in Hong Kong.

Vegzelma rose to the top of Malaysia’s bevacizumab market in the first quarter with 25% share, up from fourth place in the fourth quarter of last year, and maintained the lead in the second quarter.

Celltrion attributed the gains to a direct-sales strategy tailored to each country’s tender system and hospital demand, emphasizing stable supply and rapid response to medical institutions.

The company is also expanding engagement with physicians through major hospital collaborations and participation in local medical conferences.

“Leveraging the direct-sales capabilities of our local subsidiaries and the Celltrion brand value, we plan to drive early market establishment of our high-value follow-on product portfolio,” a Celltrion spokesperson said. “We will concentrate local business capabilities to ensure continued performance growth in the Asian region.”

About the author: World Desk

World Desk at Archynewsy.